Literature DB >> 9223425

Increased MAPK expression and activity in primary human hepatocellular carcinoma.

C M Schmidt1, I H McKillop, P A Cahill, J V Sitzmann.   

Abstract

We investigated the expression and activity of mitogen-activated protein kinase (MAPK) in human hepatocellular carcinoma (HCC). MAPK expression was determined in five human tumors and five normal tissues (adjacent non-neoplastic liver) by Western blotting using specific antisera raised against four MAPK pathway intermediates: Erk-1, Erk-2 (extracellular-signal regulated kinases), Mek-1 and Mek-2 (mitogen activated protein kinase kinases). There was a significant increase in Erk-1, Erk-2, Mek-1 and Mek-2 expression in particulate and cytosolic fractions prepared from tumor specimens as compared with the adjacent normal control tissues. The functional activity of both membrane and cytosolic Erk-2, determined by phosphorylation of myelin basic protein (MBP), was significantly increased in tumor specimens as compared to normal (membrane: 321%+/-50%, p<0.05; and cytosol: 597%+/-233%, p<0.05 percent of normal tissue). These data demonstrate for the first time a significant increase in MAPK expression and functional activity in human HCC. Because of the important role that the MAPK pathway plays in cellular growth and differentiation, overexpression of MAPK may be of critical importance to the formation and maintenance of human hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223425     DOI: 10.1006/bbrc.1997.6840

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  58 in total

1.  The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes.

Authors:  H Talarmin; C Rescan; S Cariou; D Glaise; G Zanninelli; M Bilodeau; P Loyer; C Guguen-Guillouzo; G Baffet
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

Authors:  Bert H O'Neil; Laura W Goff; John Sae Wook Kauh; Jonathan R Strosberg; Tanios S Bekaii-Saab; Ruey-Min Lee; Aslamuzzaman Kazi; Dominic T Moore; Maria Learoyd; Richard M Lush; Said M Sebti; Daniel M Sullivan
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

Review 3.  Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2010-05-28       Impact factor: 3.402

4.  Biomarkers and Personalized Sorafenib Therapy.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

5.  Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.

Authors:  Tongsen Zheng; Jiabei Wang; Xuan Song; Xianzhi Meng; Shangha Pan; Hongchi Jiang; Lianxin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-20       Impact factor: 4.553

6.  Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Authors:  Roberta Schmieder; Florian Puehler; Roland Neuhaus; Maria Kissel; Alex A Adjei; Jeffrey N Miner; Dominik Mumberg; Karl Ziegelbauer; Arne Scholz
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

Review 7.  Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.

Authors:  Josephine Chou; Yu-Ching Lin; Jae Kim; Liang You; Zhidong Xu; Biao He; David M Jablons
Journal:  Head Neck       Date:  2008-07       Impact factor: 3.147

8.  Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.

Authors:  W Chen; J L Martindale; N J Holbrook; Y Liu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.

Authors:  Sabrina C Wentz; Huangbing Wu; Michele T Yip-Schneider; Matthew Hennig; Patrick J Klein; Judith Sebolt-Leopold; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2007-11-07       Impact factor: 3.452

10.  The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.

Authors:  Patrick J Klein; C Max Schmidt; Chad A Wiesenauer; Jennifer N Choi; Earl A Gage; Michele T Yip-Schneider; Eric A Wiebke; Yufang Wang; Charles Omer; Judith S Sebolt-Leopold
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.